| 17th week of 2013 patent applcation highlights part 48 |
| Patent application number | Title | Published |
|---|
| 20130102459 | Inorganic/Organic Hybrid Totally Porous Metal Oxide Particles, Methods For Making Them And Separation Devices Using Them - The present invention is a process for making an inorganic/organic hybrid totally porous spherical silica particles by self assembly of surfactants that serve as organic templates via pseudomorphic transformation. | 2013-04-25 |
| 20130102460 | POLYANILINE-GRAPHITE NANOPLATELET MATERIALS - Nanocomposite adsorbent materials and methods for their preparation and use are described. As an example, a polyaniline-graphite nanoplatelet nanocomposite may be used to adsorb carbon dioxide. | 2013-04-25 |
| 20130102461 | Absorbent Sheet and Method for Producing Same - The present invention provides a method for producing an absorbent sheet containing absorbent resins, hydrophilic fibers, and hydrophobic fibers, comprising: a dehydration step of dehydrating the absorbent resins and the hydrophilic fibers from a state of being in contact with each other and containing water to obtain composite compositions; and a sheet-forming step of forming a sheet of the composite compositions and the hydrophobic fibers by heating while bringing the composite compositions and the hydrophobic fibers into contact with each other. | 2013-04-25 |
| 20130102462 | Process for Producing Imine Compounds for Combating Invertebrate Pests - The present invention relates to a process for producing aromatic carbonyl compounds of formula I and aromatic imine compounds of formula III | 2013-04-25 |
| 20130102463 | Herbicidal Compositions - The present invention relates to herbicidal compositions comprising as herbicide A at least one protoporphyrinogen-IX oxidase inhibitor (PPO inhibitor), and at least one light detoxifying compound B, compositions comprising them and their use as herbicides, i.e. for controlling harmful plants, and also a method for controlling unwanted vegetation which comprises allowing a herbicidal effective amount of said herbicidal composition to act on plants, their seed and/or their habitat. | 2013-04-25 |
| 20130102464 | USE OF A NATURAL EXTRACT OF GRAPE MARC FOR PROMOTING PLANT GROWTH - The invention relates to the use of an extract of grape marc for promoting plant growth and to a method for promoting plant growth which comprises the application of a composition comprising an extract of grape marc to said plants. | 2013-04-25 |
| 20130102465 | USE OF A NATURAL METABOLITE TO INCREASE CROP PRODUCTION - Described are compositions and methods to increase bud break in order to increase aspects of one or both of plant vegetative and reproductive growth, by use of a natural metabolite. In particular, the present disclosure provides a natural metabolite either alone or as part of a fertilizer blend to increase crop production. Additionally the present disclosure provides a natural metabolite in combination with one or both of a plant growth regulator and a bio stimulant to increase crop production. | 2013-04-25 |
| 20130102466 | Treatment of Plants, Fruits and Vegetables to Increase Growth, Eliminate Insects and Increase Shelf-Life with Aloe Vera Gel - The present invention includes compositions and methods for the treatment of plants against pathogens, elimination of insects and to increase the shelf-life of fruits and vegetables that includes coating the plant with undiluted aloe vera gel. | 2013-04-25 |
| 20130102467 | Biocide Compositions Comprising Derivatives of Pyroglutamic Acid - Described are agrochemical compositions, comprising (a) esters and/or amides of pyroglutamic acid, and (b) biocides. The compositions are clear and exhibit an improved stability even when stored at temperatures between 5° and 40° C. over a longer period. | 2013-04-25 |
| 20130102468 | 6-ACYL-1,2,4-TRIAZINE-3,5-DIONE DERIVATIVE AND HERBICIDES - Disclosed are compounds exhibiting sufficient herbicidal activity at low application dosage when they are applied to soils and foliage, and an agrochemical composition using the same, in particular herbicides. The compounds are triazine derivatives represented by following Formula 1 or salts thereof, and the herbicides containing them: [Chem. 28] wherein in the formula, R | 2013-04-25 |
| 20130102469 | Method and compound for removing flora from sewer lines - This invention relates to the application of herbicides in sewer lines to kill tree roots inside the lines and preventing re-growth into the lines for years after application. It relates to the discovery that latex polymers, organosilicone surfactants, deposition agents and other surfactants can be used to “glue” the herbicides to pipe surfaces. This discovery allows the use of plant killing herbicides to treat roots in sewer lines—killing them—which results in their subsequent removal by decay and erosion processes. It also allows for the use of the herbicides to prevent re-growth back into the sewer lines by applying the herbicides in a compound which adheres to the sewer line surfaces and forms a long term coating on the pipe and joint surfaces where the roots might attempt to grow back in. The compound resists erosion and washing away preventing long term root re-infestations in the sewer lines. | 2013-04-25 |
| 20130102470 | GRANULAR TURF SAFE MESOTRIONE COMPOSITIONS - A composition comprising herbicidal mixtures of mesotrione impregnated into or coated on the surface of a granular substrate material such as a fertilizer granule and/or a solid inert carrier material is provided for use to control weeds in turfgrasses without causing damage to the grass and methods for the use thereof. | 2013-04-25 |
| 20130102471 | FORMULA COMPOSITION AS DELIVERY SYSTEM USED IN PHARMACEUTICAL AND PESTICIDE APPLICATIONS - The present invention is a formula composition that acts as an efficient delivery system to transport active components to their desired target sites in the bodies of human, animal, or plant species. This formula composition is comprised of d-Limonene (C10H16), Glycol EB (2-Butoxyethanol), Calimulse PRS (Benzenesulfonic acid, C10-16-alkyl derivatives, compounds with 2-propanamine), Calsoft L-60 (Benzenesulfonic acid, C10-16-alkyl derivatives, sodium salts, Sodium xylene sulfonate, sodium sulfate), Isopar M Solvent (Light Hydrotreated Petroleum Distillates), and water. This formula composition has both pharmaceutical and agricultural product applications, due to its ability to emulsify certain active components, preserve active components in their intact form, quickly deliver them to their target sites in the body, and increase their absorptions. The formula composition in the present invention performs above functions through the synergy of its components, as well as its excellent capacity of membrane transportation. | 2013-04-25 |
| 20130102472 | PERSISTENT-MODE HIGH-TEMPERATURE SUPERCONDUCTING SHIM COILS TO ENHANCE SPATIAL MAGNETIC FIELD HOMOGENEITY FOR SUPERCONDUCTING MAGNETS - A persistent-mode High Temperature Superconductor (HTS) shim coil is provided having at least one rectangular shaped thin sheet of HTS, wherein the thin sheet of HTS contains a first long portion, a second long portion parallel to first long portion, a first end, and a second end parallel to the first end. The rectangular shaped thin sheet of high-temperature superconductor has a hollow center and forms a continuous loop. In addition, the first end and the second end are folded toward each other forming two rings, and the thin sheet of high-temperature superconductor has a radial build that is less than 5 millimeters (mm) and able to withstand very strong magnetic field ranges of greater than approximately 12 Tesla (T) within a center-portion of a superconducting magnet of a superconducting magnet assembly. | 2013-04-25 |
| 20130102473 | SUPERCONDUCTING MAGNET AND METHOD OF PRODUCING SAME - A superconducting magnet includes a superconducting wire including magnesium diboride; a superconducting coil where a part of the superconducting wire is wound; and a joint where an end of the superconducting wire and an end of another superconducting wire are connected and united. The joint includes a sintered body including magnesium diboride, an averaged particle diameter of magnesium diboride at the joint of the superconducting wire is greater than an averaged particle diameter of the magnesium diboride at the part where the superconducting wire is wound. | 2013-04-25 |
| 20130102474 | TERMINAL STRUCTURE OF SUPERCONDUCTING CABLE CONDUCTOR AND TERMINAL MEMBER USED THEREIN - In a terminal structure of a superconducting cable conductor, a terminal portion of the superconducting cable conductor is connected with a terminal member of a good conductor. The terminal portion includes a superconducting layer disposed on an outer periphery of a central support; and an insulating layer surrounding the superconducting layer. The insulating layer and the superconducting layer are partially removed to expose the central support and the superconducting layer in this order from an end of the superconducting cable conductor. The terminal member includes a metal sleeve which includes a first cylindrical portion whose inner surface is in close contact with an exposed portion of the central support; a second cylindrical portion which is soldered around an exposed portion of the superconducting layer; and a third cylindrical portion into which the insulating layer is inserted. | 2013-04-25 |
| 20130102475 | Composite Biaxially Textured Substrates Using Ultrasonic Consolidation - A method of forming a composite sheet includes disposing an untextured metal or alloy first sheet in contact with a second sheet in an aligned opposing position; bonding the first sheet to the second sheet by applying an oscillating ultrasonic force to at least one of the first sheet and the second sheet to form an untextured intermediate composite sheet; and annealing the untextured intermediate composite sheet at a temperature lower than a primary re-crystallization temperature of the second sheet and higher than a primary re-crystallization temperature of the first sheet to convert the untextured first sheet into a cube textured sheet, wherein the cube texture is characterized by a φ-scan having a FWHM of no more than 15° in all directions, the second sheet remaining untextured, to form a composite sheet. | 2013-04-25 |
| 20130102476 | COMBINED CGH & ALLELE SPECIFIC HYBRIDISATION METHOD - The invention combines the fields of comparative genomic hybridisation (CGH) analysis and SNP array analysis. It relates to methods for detecting and mapping genetic abnormalities associated with various diseases. In particular the invention provides a method for simultaneously performing array CGH and SNP array analysis on a genomic DNA sample comprising contacting a nucleic acid array which comprises a first probe set and a second probe set with a genomic DNA sample, comprising a test and reference sample, under hybridisation conditions, comparing the amount of test sample and reference sample hybridised to the hybridisation probes of the first probe set, comparing the amount of test sample and reference sample hybridised to the hybridisation probes of the second probe set; and using the data obtained to determine the copy number of at least one locus; and at least one SNP in the genomic DNA sample. | 2013-04-25 |
| 20130102477 | BIOMARKERS FOR NON-HODGKIN LYMPHOMAS AND USES THEREOF - The disclosure provides a method of identifying a subject as having B-cell non-Hodgkin lymphoma (NHL) such as testing a sample from a subject for a mutation in one or more biomarkers. Also described are methods for classifying or monitoring a subject having, or suspected of having, B-cell non-Hodgkin lymphoma comprising testing the sample for a mutation in one or more biomarkers. | 2013-04-25 |
| 20130102478 | INTERNAL STANDARDS AND METHODS FOR USE IN QUANTITATIVELY MEASURING ANALYTES IN A SAMPLE - The invention provides methods for quantitatively analyzing a plurality of analytes in a sample. Also described are general and specific internal standards useful in such analysis. In particular embodiments, these standards are described as useful in liquid chromatography/mass spectroscopy systems, which are also described herein. Moreover, in certain embodiments, the quantification methods of the present invention are useful in increasing the precision and/or accuracy of multiple analyte quantification for analytes contained in a single sample mixture using known analyte derivatives simultaneously analyzed, and compared to the unknown analytes. | 2013-04-25 |
| 20130102479 | METHODS OF ENHANCING PLURIPOTENTCY - We provide for the use of Tbx3 (GenBank Accession Number: NM_005996.3 (SEQ ID NO. 1), NP_005987.3 (SEQ ID NO. 2), NM_016569.3 (SEQ ID NO. 3), NP_057653.3 (SEQ ID NO. 4)) in a method of enhancing or inducing pluripotency in a cell such as a somatic cell. We describe a method of reprogramming a cell, the method comprising modulating the expression and/or activity of Tbx3 in the cell. The cell may become a pluripotent cell such as a stem cell. We further describe a method of causing a cell such as a somatic cell to display one or more characteristics of a pluripotent cell, the method comprising modulating the expression and/or activity of Tbx3 in the cell. The method may further comprise modulating the expression and/or activity of one or more, a combination of or all of Oct4, Sox2 and Klf4 in the cell. | 2013-04-25 |
| 20130102480 | PREDICTION DEVICE, PREDICTION METHOD, PROGRAM, AND RECORDING MEDIUM - The present invention provides a prediction device, a prediction method, a program, and a recording medium, with which whether or not desired aptamer sequences are enriched can be predicted easily. The prediction device of the present invention | 2013-04-25 |
| 20130102481 | Fluorescence Scanning Head With Multiband Detection - In a scanning system for the detection and discrimination of a plurality of targets in each of a plurality of samples, one or more multiband fluorescence detection channels each of which contains a single multiband emission filter and a single detector replaces multiple detection components in scanning heads of the prior art. In certain embodiments, a single multi-emitter light source is used as well, to illuminate each sample with excitation light at a variety of distinct wavelengths in succession. | 2013-04-25 |
| 20130102482 | COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF BREAST AND OVARIAN CANCER - The invention relates to newly discovered nucleic acid molecules and proteins associated with breast or ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast or ovarian cancers are provided. | 2013-04-25 |
| 20130102483 | METHODS FOR THE ANALYSIS OF BREAST CANCER DISORDERS - The present invention relates to methods, arrays and computer programs for assisting in classifying breast cancer diseases. In particular the invention relates to classifying breast cancer disorders by determining the methylation status of one or more sequences according to SEQ ID NO: 1-111. The classification may be further strengthened by also taking the expression levels of one or more proteins into account. | 2013-04-25 |
| 20130102484 | METHOD FOR THE DETECTION OF GENE TRANSCRIPTS IN BLOOD AND USES THEREOF - The present invention relates generally to the identification of biomarkers of conditions including disease and non disease conditions as well as identifying compositions of biomarkers. The invention further provides a method of diagnosing disease, monitoring disease progression, and differentially diagnosing disease. The invention further provides for kits useful in diagnosing, monitoring disease progression and differentially diagnosing disease. | 2013-04-25 |
| 20130102485 | Method of Determining a Diseased State in a Subject - A method includes a step of identifying candidate miRNA-mRNA complexes where an mRNA sequence from a set of mRNA sequences stably hybridizes to a miRNA from a set of miRNA sequences. The candidate miRNA-mRNA complexes have stably hybridizing sub-regions of a downstream region to portions of a 5′ miRNA section and stably hybridizing sub-regions of an upstream region to portions of a 3′ miRNA section. Candidate mRNA and/or miRNA sequences are identified as sequences that form candidate microRNA-mRNA complexes. Differences between expression levels between candidate mRNA and/or miRNA sequences in subjects having a disease and subjects not having the disease are determined for each candidate mRNA and/or miRNA sequence to identify candidate mRNA sequences and/or miRNA sequences. The expression levels of each candidate RNA disease markers are compared to controls such that deviation of expression levels of the candidate RNA disease markers from the controls indicates presence of the disease. | 2013-04-25 |
| 20130102486 | PERP AS A PROGNOSTIC AND DIAGNOSTIC MARKER FOR DYSPLASIA AND CANCER - Methods for prognosis and diagnosis of dysplasia and cancer are disclosed. In particular, the invention relates to the use of the biomarker PERP, a desmosome protein involved in cell adhesion and apoptosis, for aiding diagnosis, prognosis, and treatment of dysplasia and cancer. | 2013-04-25 |
| 20130102487 | PLASMA MICRORNAS FOR THE DETECTION OF EARLY COLORECTAL CANCER - The present invention relates in general to the field of colorectal cancer detection, and more particularly, to plasma microRNAs for the detection of early colorectal cancer. Specifically, the present invention includes methods, kits and biomarkers for diagnosing or detecting colorectal neoplasia in a human subject comprising the steps of: A method for diagnosing or detecting colorectal neoplasia in a human subject comprising the steps of: obtaining one or more biological samples from the subject suspected of suffering from colorectal neoplasia; measuring an overall expression pattern or level of one or more microRNAs obtained from the one or more biological samples of the subject; and comparing the overall expression pattern of the one or more microRNAs from the biological sample of the subject suspected of suffering from colorectal neoplasia with the overall expression pattern of the one or more microRNAs from a biological sample of a normal subject, wherein the normal subject is a healthy subject not suffering from colorectal neoplasia, wherein overexpression of a combination of miR19a and miR19b, or miR19a and miR19b and miR15b is indicative of colorectal cancer. | 2013-04-25 |
| 20130102488 | Methods of Detecting Cervical Cancer - Methods of detecting cervical dysplasia, such as cervical dysplasia likely to progress to carcinoma in a sample of human cervical cells, are provided. Methods of detecting changes in expression of one or more microRNAs or mRNAs associated with cervical dysplasia or cervical cancer are also provided. Compositions and kits are also provided. | 2013-04-25 |
| 20130102489 | SYSTEMS AND METHODS FOR HIGH-THROUGHPUT DETECTION OF AN ANALYTE IN A SAMPLE - Provided are high-throughput detection systems. The systems include a magnetic sensor device, a magnetic field source and a reservoir plate that includes a plurality of fluid reservoirs. The magnetic sensor device includes a support with two or more elongated regions each having a magnetic sensor array disposed at a distal end. Also provided are methods in which the subject high-throughput detection systems find use. | 2013-04-25 |
| 20130102490 | METHOD FOR COUNTING CHROMATID COPY NUMBERS IN A SINGLE CELL - The present invention provides a method for counting the absolute copy number of a nucleic acid sequence in a cell, which comprises the following steps: (i) dividing a lysate of the cell or a lysate of a sample of the cell into a plurality aliquots: (ii) providing conditions suitable for the amplification of the nucleic acid sequence in each aliquot: (iii) counting the number of aliquots in which the nucleic acid was amplified in step (ii) and directly deducing the copy number of the nucleic acid sequence in a cell. The method may be used to count chromatid copy number, for example to investigate the ploidy of a cell such as an oocyte or an embryo-derived cell. | 2013-04-25 |
| 20130102491 | METHOD FOR THE DIAGNOSIS OF TUBERCULOSIS - A method for the diagnosis of a tuberculosis infection caused by Mycobacteria belonging to the Mycobacteria tuberculosis complex group (MTC) in an animal including a human being, which comprises in vitro-detection of cell-mediated immune response to OmpAtb and/or antibodies against OmpAtb in a sample taken from that animal. | 2013-04-25 |
| 20130102492 | GENE EXPRESSION MARKERS FOR COLORECTAL CANCER PROGNOSIS - A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject. | 2013-04-25 |
| 20130102493 | GENE EXPRESSION ANALYSES FOR CHARACTERIZING AND IDENTIFYING GENOTOXIC COMPOUNDS - The invention relates to a method for screening compounds with (pro-)genotoxic activity by providing a cellular system being capable of expressing at least a panel of 11 defined genes, incubating at least a portion of the system with compounds to be screened, and comparing the expression of the genes in the system with the gene expression in a control cellular system, thereby detecting the (pro-)genotoxic activity. Another object of the invention concerns a method for monitoring physiological and/or pathological conditions, which are caused, mediated and/or propagated by the genetic deregulation of proliferation, differentiation and/or damage repair, by administering an effective amount of at least a single (pro-)genotoxic compound to a mammal in need of such treatment and determining an expression of 11 defined genes in a biological sample withdrawn from the mammal. The invention also relates to arrays for screening compounds with (pro-)genotoxic activity comprising nucleic acid probes that specifically hybridize under stringent conditions with the marker genes of Table 1, FIG. | 2013-04-25 |
| 20130102494 | NOVEL ANTIBODY FOR THE DIAGNOSIS AND/OR PROGNOSIS OF CANCER - The present invention relates to the field of prognosis and/or diagnosis of a proliferative disease in a patient. More particularly, the invention relates to novel antibodies capable of binding specifically to the human cMet receptor, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of said antibodies, and corresponding process, for detecting and diagnosing pathological hyperproliferative oncogenic disorders associated with expression of cMet. In certain embodiments, the disorders are oncogenic disorders associated with increased expression of cMet polypeptide relative to normal or any other pathology connected with the over expression of c Met. The invention finally comprises products and/or compositions or kits comprising at least such antibodies for the prognosis or diagnostic of certain cancers. | 2013-04-25 |
| 20130102495 | Sperm-Specific Cation Channel, Catsper1 and Uses Therefor - Nucleic acid and protein sequences relating to a cation channel which is sperm-specific (CatSper1) are disclosed. The CatSper1 protein is shown to be specifically expressed in sperm and to be necessary for sperm motility. Nucleic acids, vectors, transformed cells, transgenic animals, polypeptides, and antibodies relating to the CatSper1 gene and protein are disclosed. Also provided are methods of in vitro fertilization and contraception, methods of identifying modulators of CatSper1 activity, methods of genotyping subjects with respect to CatSper1, and methods of diagnosing and treating CatSper1-mediated disorders, including infertility. | 2013-04-25 |
| 20130102496 | ANTIGEN SCREENING SYSTEM - Methods and compositions for identifying antigens of human lymphocytes are provided herein. | 2013-04-25 |
| 20130102497 | ASSAY FOR DRUG DISCOVERY BASED ON IN VITRO DIFFERENTIATED CELLS - Provided are assay systems for determining the therapeutic or toxic effect of a putative drug based on assaying its activity in cells which have been differentiated in vitro from stem cells, and induced to display a phenotype that resembles a disease to be treated. | 2013-04-25 |
| 20130102498 | COMPOSITIONS AND METHODS FOR DETECTING AMYLOID-BETA-DEGRADING ENZYME ACTIVITY - Novel substrates for detection of activity of amyloid beta degrading enzyme, such as Neprilysin (NEP) and insulin degrading enzyme (IDE), associated with Alzheimer's disease, are provided. A quenched fluorogenic peptide substrate containing the first seven residues of the Aβpeptide plus a C-terminal Cys residue to detect neprilysin activity with a fluorophore attached to the C-terminal Cys and a quencher linked to the N-terminus of the peptide is disclosed. An assay system sensitive to endopeptidase activity of NEP and IDE, but insensitive to other Aβ-degrading enzymes is disclosed. Active compounds are identified by a cell-based assay system for high-throughput screening. | 2013-04-25 |
| 20130102499 | METHOD FOR DETERMINATION OF ACTIVITY OF MITOCHONDRIAL DNA POLYMERASE OF FALCIPARUM MALARIA, AND METHOD FOR SCREENING FOR ANTI-MALARIA COMPOUND - An object is to provide a means which is useful for the development of an anti-malaria agent. It was found that a mitochondrial DNA polymerase of falciparum malaria shows a bivalent iron ion requirement. Thus, disclosed is a method for measuring the activity of a DNA polymerase, including the steps of: (1) incubating a solution containing a bivalent iron ion, a mitochondrial DNA polymerase of falciparum malaria, template DNA, and at least one deoxyribonucleoside triphosphate or deoxyribonucleoside triphosphate derivative; (2) detecting the synthesized double-stranded DNA; and (3) calculating the activity of the DNA polymerase from the result of the detection carried out in step (2). | 2013-04-25 |
| 20130102500 | Microarray Comprising Immobilisation Particles - A microarray comprises a carrier substrate and a plurality of immobilization particles configured to immobilize capture molecules. Each immobilization particle comprises a first sub-section bonded to the carrier substrate and a second sub-section which is exposed. | 2013-04-25 |
| 20130102501 | DEVICE FOR RECOVERY AND ISOLATION OF BIOMOLECULES - The present invention relates to a device for isolating and recovering a biomolecule from a test sample. The device includes a support and at least one peelable layer deposited on at least a portion of the support. The peelable layer includes a substrate having a target component immobilized on the substrate. The device is effective for isolating and recovering a biomolecule having affinity to the target component. The present invention also relates to systems and methods of using the device. The present invention also relates to a biomolecule elution strip and related methods. | 2013-04-25 |
| 20130102502 | BIO-CHIP - There is provided a bio-chip including a first substrate including a first recess formed in a first end surface thereof; and a second substrate including a first coupling pillar inserted into the first recess and a second coupling pillar in contact with a second end surface opposed to the first end surface. | 2013-04-25 |
| 20130102503 | CLARIFYING AND STABILIZING COMPOSITION - An aqueous composition, a solid composition and method for producing the solid composition are disclosed. The aqueous and solid compositions may be used in a number of applications such as in processes to recover oil from a production well containing an oil slug and in processes to clarify aqueous slurries containing sedimentation. The compositions comprise a surfactant, a pre-gelatinized starch, an inorganic salt, an oil and a polymer. The method of manufacturing the solid composition includes exposing the aqueous composition to temperatures around 0 degrees F. A solid block stable at ambient temperatures is formed along with a liquid phase that may be separated from the solid block. Dispersing the solid composition in water further enhances flow stability. | 2013-04-25 |
| 20130102504 | PROCESS FOR PRODUCING MINERAL OIL USING SURFACTANTS BASED ON A MIXTURE OF C20 GUERBET-, C22 GUERBET-, C24 GUERBET-CONTAINING HYDROCARBYL ALKOXYLATES - The present invention relates to a surfactant mixture comprising at least three ionic surfactants which differ in terms of the hydrocarbyl moiety (R | 2013-04-25 |
| 20130102505 | PROCESS FOR PRODUCING MINERAL OIL USING SURFACTANTS BASED ON A MIXTURE OF C28 GUERBET, C30 GUERBET, C32 GUERBET-CONTAINING HYDROCARBYL ALKOXYLATES - The present invention relates to a surfactant mixture comprising at least three ionic surfactants which differ in terms of the hydrocarbyl moiety (R | 2013-04-25 |
| 20130102506 | LUBRICANT BASE OIL AND LUBRICANT COMPOSITION - A lubricating base oil includes at least one of ionic liquids containing a compound represented by a formula (1): Z | 2013-04-25 |
| 20130102507 | POLYALKYLENE GLYCOL LUBRICANT COMPOSITION - A lubricant composition useful for automotive engines, comprising: (A) at least one polyalkylene glycol suitable for use as a lubricant in an automotive engine, (B) an additive package which comprises an acid scavenger, wherein the acid scavenger is an aspartic acid ester, aspartic acid amide, a Group V aspartic acid salt, or a combination thereof. | 2013-04-25 |
| 20130102508 | Lubricating Composition Containing Multifunctional Hydroxylated Amine Salt Of A Hindered Phenolic Acid - Multi-functional additives which impart improved antioxidancy to lubricating oil compositions and frictional properties resulting in improved fuel economy in an internal combustion engine are disclosed. More particularly disclosed are lubricating oil compositions for internal combustion engines comprising a) a major amount of an oil of lubricating viscosity; and b) a minor amount of an oil soluble hydroxylated amine salt of a hindered phenolic acid, said salt having the general formula I: | 2013-04-25 |
| 20130102509 | LUBRICATING COMPOSITION FOR USE IN DIESEL ENGINES COMPATIBLE WITH BIOFUEL - A method of operating a diesel engine comprises lubricating the diesel engine with a lubricating composition and using a biofuel as fuel, wherein the lubricating composition comprises a base oil belonging to Group III or Group II of the API base oil categories, from 0.5 to 5% by mass of a phenolic anti-oxidant, and from 0.5 to 5% by mass of an amine-based anti-oxidant, the total content of the anti-oxidants being at least 2% by mass. | 2013-04-25 |
| 20130102510 | ESTOLIDE COMPOSITIONS EXHIBITING HIGH OXIDATIVE STABILITY - Provided herein are estolide compositions having high oxidative stability, said compositions comprising at least one compound of formula: | 2013-04-25 |
| 20130102511 | Additive Concentrate and a Method of Lubricating Transmissions - The present invention relates to an additive concentrate comprising a friction modifier, a corrosion inhibitor, and an oil of lubricating viscosity. The invention further provides a method for lubricating a transmission using the additive concentrate. | 2013-04-25 |
| 20130102512 | COMPOSITION FOR STRIPPING COLOR FILTER AND REGENERATION METHOD OF COLOR FILTER USING THE SAME - A composition for stripping a color filter and a color filter regeneration method are provided. A composition for stripping the color filter according to an exemplary embodiment of the present invention includes glycol and potassium hydroxide (KOH), in which either (a) the concentration of the glycol is in the range of 83 wt % to 91 wt % and of the concentration of the potassium hydroxide satisfies the condition: (wt % of KOH)≧6−(0.065*(wt % of the glycol)), or (b) the concentration of glycol is more than 91 wt % and the concentration of potassium hydroxide (KOH) is more than 0.2 wt %. | 2013-04-25 |
| 20130102513 | AQUEOUS HAIR CLEANSING AGENT - The aqueous hair cleansing agent of the present invention contains components (A), (B), (C), and (D) below:
| 2013-04-25 |
| 20130102514 | FORMULATIONS, THEIR USE AS OR FOR PRODUCING DISHWASHING COMPOSITIONS AND THEIR PREPARATION - Formulations comprising
| 2013-04-25 |
| 20130102515 | FORMULATIONS, THEIR USE AS OR FOR PRODUCING DISHWASHING COMPOSITIONS AND THEIR PREPARATION - Formulations comprising
| 2013-04-25 |
| 20130102516 | FORMULATIONS, THEIR USE AS OR FOR PRODUCING DISHWASHING DETERGENTS AND THEIR PRODUCTION - Formulations comprising
| 2013-04-25 |
| 20130102517 | PARTICLE - A core-shell particle wherein the core comprises an aminocarboxylic builder and the shell comprises a water-soluble inorganic salt. | 2013-04-25 |
| 20130102518 | DETERGENT COMPOSITION CONTAINING AN AMPS COPOLYMER AND A PHOSPHONATE - Detergent compositions including at least one AMPS copolymer, at least one organophosphonate, an alkaline agent and an optional complexing agent are disclosed. Embodiments of the present invention reduce scale accumulation and provide stain removal capability for warewash applications. | 2013-04-25 |
| 20130102519 | CONTINUOUS PROCESS OF MAKING A FABRIC SOFTENER COMPOSITION - A continuous process of making a fabric softener composition comprising di(C6-C14)alkyl di(C1-C4 alkyl and/or hydroxyalkyl) quaternary and perfume, and a fabric softener composition obtained by the continuous process. The fabric softener composition obtained by the continuous process demonstrates a stable viscosity, especially while being stored for a prolonged period of time. | 2013-04-25 |
| 20130102520 | THICKENED FABRIC SOFTENER - A thickened fabric softener includes 1 to 5 wt % textile-softening compound and a selected C | 2013-04-25 |
| 20130102521 | COMPOSITIONS FOR OXYGEN TRANSPORT COMPRISING A HIGH OXYGEN AFFINITY MODIFIED HEMOGLOBIN - The present invention relates to blood products, and more particularly to compositions comprising a modified oxygenated hemoglobin having a high affinity for oxygen and methods for making such compositions. Such compositions according to the present invention have better stability to auto oxidation and superior oxygen carrying characteristics. | 2013-04-25 |
| 20130102522 | INHIBITORS OF PROTEIN KINASES AND USES THEREOF - Compounds that are capable of inhibiting the activity of one or more protein kinases are provided. The compounds are short, predominantly basic peptidic compounds comprising between about 5 and about 20 amino acids, and can optionally comprise an ATP mimetic moiety. The protein kinase inhibiting compounds can be used to inhibit the activity of one or more protein kinases in vitro or in vivo. Also provided are methods of inhibiting a protein kinase in a subject by administration of an effective amount of a protein kinase inhibiting compound and the use of the protein kinase inhibiting compounds, alone or in combination with other chemotherapeutic agents, in the treatment of protein kinase mediated diseases and disorders. | 2013-04-25 |
| 20130102523 | THERAPEUTIC COMBINATION OF DAPTOMYCIN AND PROTEIN SYNTHESIS INHIBITOR ANTIBIOTIC, AND METHODS OF USE - A therapeutic combination comprises an antibacterially effective amount of daptomycin, and an amount of protein synthesis inhibitor antibiotic effective to prevent the development of daptomycin non-susceptibility in bacteria. Related combination therapies and methods are also included. | 2013-04-25 |
| 20130102524 | Compounds And Their Use - The present invention relates to peptides and their use in the treatment of microbial infections, in particular bacterial infections. In particular, the invention relates to peptides wherein at least 75% of the amino acids of the peptide are arginine and phenylalanine amino acids, at least 50% of the amino acids being arginine amino acids and at least 15% of the amino acids being phenylalanine amino acids. | 2013-04-25 |
| 20130102525 | Methods for Treating HCV - The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin. | 2013-04-25 |
| 20130102526 | Methods for Treating HCV - The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir). | 2013-04-25 |
| 20130102527 | INHIBITORS OF THE TRYPSIN-LIKE SITE OF THE PROTEASOME AND METHODS OF USE THEREOF - The present invention is an inhibitor of the trypsin-like β2/β2i sites of the proteasome. The inhibitor is characterized as being a peptide-based epoxyketone or vinyl sulfone that contains an arginine or 4-aminomethylene-L-phenylalanine at the C-terminus (i.e., at the P1 position). Methods for using the inhibitor to inhibit the activity of the β2/β2i site of a proteasome and treat a proteasome-mediated disease or condition are also described. | 2013-04-25 |
| 20130102528 | Methods and Pharmaceutical Composition for the Treatment of a Feeding Disorder with Early-Onset in a Patient - The present invention relates to a compound which is an agonist of the oxytocin receptor o for use in the treatment of a feeding disorder with early-onset. In a particular embodiment, the agonist of the oxytocin receptor is the oxytocin or an active fragment thereof. | 2013-04-25 |
| 20130102529 | IRON (III) CASEINSUCCINYLATE AND METHOD FOR THE PREPARATION THEREOF - The present invention refers to an iron (III) caseinsuccinylate characterised by a content of iron comprised between 4.5% and 7% by weight, and by a solubility in water approximately greater than 92%. | 2013-04-25 |
| 20130102530 | Protection, Restoration and Enhancement of Erythropoietin-Responsive Cells, Tissues and Organs - Methods and compositions are provided for protecting or enhancing an erythropoietin-responsive cell, tissue, organ or body part function or viability in vivo, in situ or ex vivo in mammals, including human beings, by systemic or local administration of an erythropoietin receptor activity modulator, such as an erythropoietin or a modified erythropoietin. | 2013-04-25 |
| 20130102531 | FUNCTIONAL VASCULARIZATION WITH BIOCOMPATIBLE POLYSACCHARIDE-BASED HYDROGELS - Slow vascularization of functional blood limits the transplantation of tissue constructs and the recovery of ischemic and wounded tissues. Blood vessel ingrowth into polysaccharide-based hydrogel scaffolds remains a challenge. A synergistic effect of multiple angiogenic GFs was established; the co-encapsulation of VEGF plus other growth factors induced more and larger blood vessels than any individual GF, while the combination of all GFs dramatically increased the size and number of newly formed functional vessels. Rapid, efficient, and functional neovascularization may be achieved. | 2013-04-25 |
| 20130102532 | HB-EGF Composition and Use Thereof to Treat a Condition Associated With Enhanced Urothelium Permeability - HB-EGF is exploited to treat conditions associated with enhanced urothelium permeability, including interstitial cystitis. | 2013-04-25 |
| 20130102533 | ALBUMIN FUSION PROTEINS - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention. | 2013-04-25 |
| 20130102534 | COMPOSITIONS AND METHODS FOR TREATING PATHOLOGIC ANGIOGENESIS AND VASCULAR PERMEABILITY - Compounds, compositions and methods for inhibiting vascular permeability and pathologic angiogenesis are described herein. Methods for producing and screening compounds and compositions capable of inhibiting vascular permeability and pathologic angiogenesis are also described herein. Pharmaceutical compositions are included in the compositions described herein. The compositions described herein are useful in, for example, methods of inhibiting vascular permeability and pathologic angiogenesis, including methods of inhibiting vascular permeability and pathologic angiogenesis induced by specific angiogenic, permeability and inflammatory factors, such as, for example VEGF, bFGF and thrombin. Methods for treating specific diseases and conditions are also provided herein. | 2013-04-25 |
| 20130102535 | Method for Preventing Myocardial Ischemia - Use of polypeptide micromolecule MLIF in preparing medicine for preventing and treating myocardial ischmia, where amino acid sequence of the polypeptide micromolecule MLIF is Met-Gln-Cys-Asn-Ser (SEQ ID NO:1). | 2013-04-25 |
| 20130102536 | COMPOSITIONS AND METHODS FOR MODULATING TOLL-LIKE RECEPTOR 2 ACTIVATION - A method of promoting hair growth of a subject includes administering to follicle cells of the subject a therapeutically effective amount of a TLR2 agonist that promotes TLR2 activation and hair growth of the subject. | 2013-04-25 |
| 20130102537 | MANUFACTURE OF FACTOR H (FH) AND FH-DERIVATIVES FROM PLASMA - The present invention provides compositions and pharmaceutical formulations of Factor H derived from plasma. Also provided are methods for the manufacture of the Factor H compositions and formulations, as well as methods for the treatment of diseases associated with Factor H dysfunction. | 2013-04-25 |
| 20130102538 | METHOD OF TREATING ALZHEIMER'S DISEASE USING PHARMACOLOGICAL CHAPERONES TO INCREASE PRESENILIN FUNCTION AND GAMMA-SECRETASE ACTIVITY - The present invention relates to a method for treating an individual having Alzheimer's Disease by using pharmacological chaperones that bind presenelin and thereby increase γ-secretase activity. | 2013-04-25 |
| 20130102539 | PEPTOIDS AND METHODS FOR TREATING ALZHEIMER'S DISEASE - Provided herein are peptoids capable of inhibiting or reversing amyloid β (Aβ) fibril or plaque production. The peptoids form a helical structure with three monomers per helical turn and have at least two monomers with a side-chain having an arylalkyl group having the same chirality positioned such that the side-chains are on the same side of the peptoid. Also provided are methods of using the peptoids to inhibit or reverse aggregation of Aβ and methods of treating subjects with Alzheimer's disease (AD) or slowing the progression of AD. | 2013-04-25 |
| 20130102540 | Compositions and Methods for Skin Treatment - Compositions for the treatment of the skin. The compositions reduce and/or reverse the visible appearance of skin damage. In the preferred embodiment, the composition includes Retinyl Palmitate Polypeptide; Ascorbylmethylsilanol Pectinate; Tocopheryl Polypeptide; Cholecalciferol Polypeptide; and Niacinamide Polypeptide. | 2013-04-25 |
| 20130102541 | METHODS OF INHIBITING TUMOR CELL AGGRESSIVENESS USING THE MICROENVIRONMENT OF HUMAN EMBRYONIC STEM CELLS - The invention provides compositions comprising one or more isolated factors from a microenvironment of human embryonic stem cells (hESCs), including, but not limited to, Lefty and inhibitors of Nodal. The invention also provides methods of utilizing factors derived from human embryonic stem cells (hESC) and their microenvironment to treat and prevent tumor formation and progression and to inhibit tumor cell aggressiveness. The invention further provides methods of inhibiting tumor cell growth and/or treating aggressive tumors in a mammal comprising administering to the mammal, having at least one tumor cell present in its body, an effective amount of an inhibitor of Nodal activity. | 2013-04-25 |
| 20130102542 | CANCER RELATED ISOFORMS OF COMPONENTS OF TRANSCRIPTION FACTOR COMPLEXES AS BIOMARKERS AND DRUG TARGETS - The invention is related to isoforms of components of transcription factor complexes that are specifically expressed in cancer cells. These isoforms can be used as biomarkers for detection, diagnosis, prognosis and monitoring of treatments of cancer, and as drug targets of pharmaceutical compositions for the treatment of various cancers expressing the targeted isoforms. Methods, molecules, materials and kits for these uses are disclosed. | 2013-04-25 |
| 20130102543 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR CONTRIBUTING TO THE TREATMENT OF CANCERS - Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ET | 2013-04-25 |
| 20130102544 | Disease-Associated Proteins - Disclosed are methods and compositions for early diagnosis, monitoring and treatment of an ocular disorder. In particular, the invention relates to a novel protein, that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with healthy subjects, antibodies which recognize this protein, and methods for diagnosing such conditions. | 2013-04-25 |
| 20130102545 | TEMPERATURE DEPENDENT ACTIVATION OF CATALYTIC NUCLEIC ACIDS FOR CONTROLLED ACTIVE SUBSTANCE RELEASE - The present invention relates to an active substance release system containing two compounds. The first compound comprises a nanoparticle, combined with an oligonucleotide inhibition strand that is hybridized with a catalytically active nucleic acid. The second compound comprises a carrier, combined with a substrate molecule that is coupled to a therapeutic active substance. By means of external stimulation, the catalytically active nucleic acid of the first compound is released and specifically binds to the substrate molecule of the second compound. This leads to cleavage of the substrate molecule, whereby the active substance bound thereto is released. | 2013-04-25 |
| 20130102546 | METHODS OF TREATING VASCULAR INFLAMMATORY DISORDERS - Provided are methods of treating or delaying the onset of a vascular inflammatory disease (e.g., acute lung injury) in a subject including administering to the subject a therapeutically effective amount of a nucleic acid containing all or a part of the sequence of mature miR-181b (SEQ ID NO: 1). Also provided are methods of decreasing nuclear factor-R? (NF-R?) signaling in an endothelial cell including administering to the subject a nucleic acid containing all or a part of the sequence of mature miR-181b (SEQ ID NO: 1). | 2013-04-25 |
| 20130102547 | Use Of Tight Junction Antagonists To Treat Inflammatory Bowel Disease - The present invention provides materials and methods for the treatment of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis). Materials of the invention may include compositions comprising one or more tight junction antagonists and optionally one or more therapeutic agents. Methods of the invention may comprise treating a subject in need thereof with a composition comprising one or more tight junction antagonists and, optionally one or more therapeutic agents. | 2013-04-25 |
| 20130102548 | PHARMACEUTICAL DELIVERY SYSTEM - A pharmaceutical formulation to treat vaginal conditions in a human patient comprises:
| 2013-04-25 |
| 20130102549 | VEGF Production Promoter - Provided are a VEGF production promoter, a hair quality improver, and an external preparation for skin, each of which has a VEGF production promoting activity and can be used as a pharmaceutical agent, a cosmetic, a food, or a material therefor. | 2013-04-25 |
| 20130102550 | AMORPHOUS ROXITHROMYCIN COMPOSITION - This invention relates to a macrolide composition, more particularly an amorphous form (Form-III) of 3R, 4S, 5S, 6R, 7R, 9R, 11S, 12R, 13S, 14R-6-[(2S, 3R, 4S, 6R)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7, 12, 13-trihydroxy-4-[(2R, 4R, 5S, 6S)-5-hydroxy-4-methoxy-4, 6-dimethyloxan-2-yl]oxy-10-(2-methoxyethoxymethoxy-imino)-3, 5, 7, 9, 11, 13-hexamethyl-1-oxacyclotetradecan-2-one or roxithromycin characterised by the absence of peaks in the infra-red spectrum of amorphous (Form-III) of roxithromycin at 3577.15; 3526.03; 3465.27 and 3276.24 cm-1 relative to the infra-red spectrum of the prior art roxithromycin raw material displaying peaks at 3577.15; 3526.03; 3465.27 and 3276.24 cm-1 and further characterised by an increased solubility of at least 50% over prior art anhydrous and monohydrated roxithromycin in acetate buffer (pH 4.5), phosphate buffer (pH 6.8) and water. | 2013-04-25 |
| 20130102551 | ANTIBIOTIC COMPOSITIONS - The invention relates to solid pharmaceutical or veterinary compositions comprising substantially pure Tulythromycin A in form of an addition salt with one or more acids, and to methods for preparing them. Following reconstitution with an aqueous solvent, the resulting solutions of Tulathromycin A may be administered to a mammal in order to treat bacterial or protozoal infections. | 2013-04-25 |
| 20130102552 | PESTICIDAL COMPOSITION AND ITS USE - A composition comprising a carboxamide compound represented by following formula (I), wherein R | 2013-04-25 |
| 20130102553 | Therapeutic Strategies For Prevention And Treatment Of Alzheimer's Disease - The invention relates to therapeutic agents for use in the prevention or treatment of Alzheimer's disease. In particular the invention relates to use of inhibitors of cell cycle reentry and progression to the G1/S transition or inhibitors of progression of the cell cycle through the G1/S transition point in the prevention or treatment of Alzheimer's disease. | 2013-04-25 |
| 20130102554 | COMPOSITION FOR TREATMENT OF OBESITY USING WHEAT BRAN EXTRACT OR ACTIVE INGREDIENT ISOLATED THEREFROM - The present invention relates to a composition for treatment of obesity using a wheat bran extract or a tachioside or 9,12,13-trihydroxy-10(E)-octadecenoic acid, an active ingredient isolated therefrom. The wheat bran extract or the active ingredients inhibit the expression of PPARγ, C/EBRα and ADD1/SREBP1c, transcription factors which inhibit the differentiation of adipocyte progenitor cells to adipocytes, promoted by insulin, inhibit the accumulation of fats, and are centrally involved in the differentiation of adipocytes. | 2013-04-25 |
| 20130102555 | METHOD OF TREATING DIABETES - Methods are provided for treating diabetes, lowering plasma level of HbA1c, glucose plasma levels, total cholesterol plasma level, and/or triglyceride plasma level while increasing HDL cholesterol levels and delaying onset of diabetic retinopathy in a diabetic, pre-diabetic, or non-diabetic mammal while minimizing undesirable side effects. | 2013-04-25 |
| 20130102556 | Use of N1,N4-bis[3-(Ethylamino)Propyl]-2-Butene-1,4-Diamine Compounds in Combination with Epigenetic-Acting Pharmaceuticals for Enhanced Cancer Therapy - Combination methods for treatment of cancer and of blood disorders, using PG-11047 ((2Z)-N1,N4-bis[3-(ethy-lammo) propyl]-2-butene-1,4-diamine) and PG-11048 ((2E)-N1,N4-bis[3-(ethylamino)propyl]-2-butene-1,4-diamine) in combination with DNA methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors, or both DNA methyltransferase inhibitors and histone deacetylase inhibitors, are disclosed. Hematopoietic cancers, lung cancers, mesothelioma, cutaneous T-cell lymphoma (CTCL), multiple myeloma, solid tumors, and blood disorders such as myelodysplastic syndromes can be treated using the methods of the invention. | 2013-04-25 |
| 20130102557 | Methods for Treating HCV - The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin. | 2013-04-25 |
| 20130102558 | Methods for Treating HCV - The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir). | 2013-04-25 |
